- Home
- MTVA vs NCRA Comparison
MTVA vs NCRA Comparison
Compare MTVA & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- NCRA
- Stock Information
- Founded
- MTVA 2014
- NCRA 2002
- Country
- MTVA United States
- NCRA Taiwan
- Employees
- MTVA N/A
- NCRA N/A
- Industry
- MTVA
- NCRA Farming/Seeds/Milling
- Sector
- MTVA
- NCRA Consumer Staples
- Exchange
- MTVA NYSE
- NCRA Nasdaq
- Market Cap
- MTVA 14.3M
- NCRA 15.4M
- IPO Year
- MTVA N/A
- NCRA N/A
- Fundamental
- Price
- MTVA $0.66
- NCRA $1.02
- Analyst Decision
- MTVA Strong Buy
- NCRA
- Analyst Count
- MTVA 2
- NCRA 0
- Target Price
- MTVA $7.50
- NCRA N/A
- AVG Volume (30 Days)
- MTVA 133.9K
- NCRA 54.7K
- Earning Date
- MTVA 08-13-2025
- NCRA 08-13-2025
- Dividend Yield
- MTVA N/A
- NCRA N/A
- EPS Growth
- MTVA N/A
- NCRA N/A
- EPS
- MTVA N/A
- NCRA N/A
- Revenue
- MTVA N/A
- NCRA $16,647,379.00
- Revenue This Year
- MTVA N/A
- NCRA N/A
- Revenue Next Year
- MTVA N/A
- NCRA N/A
- P/E Ratio
- MTVA N/A
- NCRA N/A
- Revenue Growth
- MTVA N/A
- NCRA N/A
- 52 Week Low
- MTVA $0.63
- NCRA $0.70
- 52 Week High
- MTVA $5.30
- NCRA $2.09
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- NCRA 50.60
- Support Level
- MTVA N/A
- NCRA $0.87
- Resistance Level
- MTVA N/A
- NCRA $1.05
- Average True Range (ATR)
- MTVA 0.00
- NCRA 0.07
- MACD
- MTVA 0.00
- NCRA -0.00
- Stochastic Oscillator
- MTVA 0.00
- NCRA 65.79
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.